The following is a summary of “Inspiratory hyperoxia: a new way to prevent metastasis through metabolism reprogramming in non-small cell lung cancer” published in the December 2022 issue of Respiratory by Eymin et al.

Lung cancer is one of the types of cancer diagnosed the most frequently and is also the type of cancer responsible for the greatest number of deaths caused by cancer on a global scale [1]. Non-small cell lung cancer(NSCLC), accounts for the great majority of lung cancer cases. This subtype of lung cancer is the most common. 

Over the last few decades, significant progress has been made in the clinical management of individuals afflicted with non-small cell lung cancer, also known as NSCLC. These developments started with the introduction of targeted therapies, such as inhibitors of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) in patients with EGFR-mutated NSCLC. They increased even further with the introduction of immune checkpoint inhibitors in NSCLC patients with high PD-L1 expression [2, 3]. First responder patients will invariably develop a resistance to the treatment, which is closely associated with the course of the disease. 

This is the case even when the outcomes have been spectacular. In addition, many patients with NSCLC continue to be ineligible for these treatments, and even among those for whom these drugs are appropriate, many do not react to treatment. As a consequence of this, the development of fresh methods of treatment is of the utmost importance in the field of non-small cell lung cancer (NSCLC).